INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 12, Issue 2- 2025

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.02.003

HIV and Sickle Cell Disease: Challenges in Pediatric Management

***Emmanuel Ifeanyi Obeagu**
Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com, obeague@africau.edu, ORCID: 0000-0002-4538-0161
*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, obeague@africau.edu, ORCID: 0000-0002-4538-0161

Abstract

The co-occurrence of HIV and sickle cell disease (SCD) in pediatric populations presents significant clinical challenges that require a comprehensive and multidisciplinary approach to management. Both HIV and SCD are chronic conditions with complex pathophysiology that can exacerbate each other's impact, leading to increased susceptibility to infections, frequent pain crises, and multi-organ complications. Pediatric patients with co-infection are at a higher risk of delayed growth, neurological complications, and worsened clinical outcomes. This review explores the unique challenges in diagnosing and managing HIV and SCD in children, highlighting the need for early detection, tailored treatment strategies, and close monitoring of both diseases. The management of pediatric patients with HIV and SCD requires careful coordination between hematologists, infectious disease specialists, pediatricians, and other healthcare providers. Antiretroviral therapy (ART) is critical for controlling HIV progression, but certain ART regimens may exacerbate SCD complications, requiring careful drug selection. Hydroxyurea, commonly used in SCD management, must also be administered cautiously in HIV-infected children to prevent potential immune system interference. Additionally, addressing the psychosocial aspects of care, such as medication adherence and stigma, is crucial for improving patient outcomes

Keywords: HIV, Sickle Cell Disease, Pediatric Management, Co-Infection, Treatment Strategies

Introduction

HIV and sickle cell disease (SCD) are both significant health concerns, particularly in regions with high prevalence rates, such as sub-Saharan Africa. The coexistence of these two chronic conditions in pediatric patients presents a unique and complex clinical challenge. HIV, a viral infection that primarily attacks the immune system, weakens the body's ability to fight off infections and other diseases. Sickle cell disease, a genetic blood disorder characterized by the production of abnormal hemoglobin, causes chronic anemia, painful vaso-occlusive crises, and multi-organ complications. When these two conditions co-occur in a child, they can interact in ways that exacerbate each other's negative effects, leading to more severe clinical manifestations and complications. As such, managing HIV and SCD in pediatric patients requires careful consideration of both diseases' pathophysiology, a multidisciplinary approach, and personalized treatment plans.[1-2] The prevalence of co-infection with HIV and SCD is particularly concerning in resource-limited settings where both conditions are highly prevalent. HIV affects the immune system, leading to immune dysfunction and increased vulnerability to opportunistic infections, while sickle cell disease contributes to vascular and organ dysfunction. These combined effects can result in a higher frequency of pain crises, infections, delayed growth and development, and neurological complications. The presence of HIV in children with SCD may lead to worsened morbidity and mortality, as it complicates the management of common SCD-related issues such as anemia, vaso-occlusive crises, and stroke. Additionally, the immunosuppressive nature of HIV increases the likelihood of severe complications from infections that might otherwise be manageable in children with SCD alone.[3-5]

Early diagnosis of both HIV and SCD is crucial in ensuring effective treatment and management. However, diagnosing these two conditions in children is challenging, as their clinical manifestations may overlap. The symptoms of HIV infection, such as weight loss, failure to thrive, and frequent infections, may resemble some of the complications seen in children with sickle cell disease. For example, both conditions are associated with chronic anemia and immune dysregulation, making it difficult to distinguish between them without thorough testing. Additionally, the signs of SCD-related complications, such as pain crises or stroke, could be misattributed to HIV-related immunosuppression, delaying proper treatment. Regular screening and early detection of both HIV and SCD are vital to achieving the best possible clinical outcomes for these children.[6-8] In addition to the diagnostic challenges, the treatment of pediatric patients with HIV and SCD requires a delicate balance. Antiretroviral therapy (ART) is the cornerstone of HIV treatment and aims to suppress viral replication and improve immune function. However, certain ART regimens may worsen SCD-related complications, such as kidney toxicity or bone marrow suppression. For example, some antiretroviral drugs may exacerbate anemia or reduce the production of red blood cells, both of which are already compromised in children with SCD. Conversely, therapies used to manage SCD, such as hydroxyurea, which helps reduce the frequency of vaso-occlusive crises, could potentially interfere with immune responses, complicating HIV management. Therefore, a careful and individualized approach to ART and SCD therapy is essential to ensure both diseases are managed optimally without exacerbating the other.[9-11]

The impact of co-infection with HIV and SCD on the pediatric population extends beyond the clinical aspects, encompassing psychological, social, and developmental challenges. Children living with HIV often experience stigma and discrimination, which can impact their mental health and adherence to treatment regimens. This stigma can be even more pronounced when combined with the challenges faced by children with sickle cell disease, such as frequent hospitalizations and visible symptoms. The burden of chronic illness in these children can affect their quality of life, school performance, and social interactions. Providing psychosocial support to children and their families is essential for promoting adherence to treatment, managing

mental health concerns, and improving the overall well-being of pediatric patients living with both HIV and SCD.[12-15] Managing HIV and SCD in children requires a multidisciplinary approach that involves specialists in pediatric hematology, infectious diseases, nephrology, and other relevant fields. Close coordination among healthcare providers is necessary to develop individualized treatment plans that address both diseases while minimizing potential drug interactions and side effects. Regular follow-up visits, continuous monitoring of disease progression, and ongoing support for families are crucial for managing these patients effectively. This collaborative approach can help ensure timely interventions, reduce complications, and improve the health outcomes for children living with the dual burden of HIV and sickle cell disease.[16-18]

Challenges in Diagnosis and Clinical Management

The diagnosis and clinical management of pediatric patients with both HIV and sickle cell disease (SCD) present significant challenges. One of the foremost obstacles is the overlap in clinical symptoms between HIV and SCD, which can lead to misdiagnosis or delayed identification of both conditions. For instance, both HIV and SCD can cause chronic anemia, fatigue, delayed growth, and recurrent infections, which might make it difficult to distinguish between the two. Furthermore, the immunosuppressive nature of HIV complicates the recognition of SCD-related complications, such as vaso-occlusive crises or stroke, because the typical inflammatory response to these events may be dampened. In addition, certain complications related to SCD, such as pain crises or organ damage, can be exacerbated by HIV infection, creating a diagnostic dilemma. Accurate and timely diagnosis requires thorough screening, including regular HIV testing in children at risk, as well as genetic testing and blood work to confirm the presence of SCD.[19-20]
In terms of clinical management, healthcare providers must navigate the complexities of treating two chronic conditions with distinct therapeutic approaches. Antiretroviral therapy (ART) is the mainstay of HIV treatment, yet its interaction with SCD therapies presents a challenge. ART regimens can affect bone marrow function, renal health, and blood cell production, which can be problematic for children with SCD, who already experience compromised red blood cell production and a higher risk of renal complications. For instance, some ART drugs, such as protease inhibitors, can increase the risk of nephropathy, which is a concern for children already predisposed to kidney damage due to SCD. The use of hydroxyurea to manage SCD-related pain crises and reduce the frequency of vaso-occlusive episodes also requires careful monitoring in HIV-positive children to avoid potential immune system suppression. The interplay between HIV and SCD medications requires close collaboration among pediatric hematologists, infectious disease specialists, and other healthcare providers to develop treatment regimens that are effective for both conditions without exacerbating complications.[21-23]
Psychosocial challenges further complicate the management of children with HIV and SCD. These children often face stigma and psychological distress related to their chronic illnesses. For instance, the visible symptoms of SCD, such as jaundice or frequent hospitalizations, can make children targets for discrimination, while the stigma of living with HIV can affect self-esteem and mental health. Furthermore, managing adherence to complex treatment regimens for both HIV and SCD can be difficult, particularly when children are required to take multiple medications with varying dosages and schedules. The added psychological burden of living with two chronic conditions, along with the challenges of managing pain, can negatively affect a child's quality of life. Therefore, comprehensive care that includes psychosocial support, counseling, and strategies to improve medication adherence is essential for optimizing treatment outcomes and overall well-being in these pediatric patients.[24-26] Additionally, the healthcare infrastructure and resources in low-resource settings can be a significant barrier to effective diagnosis and management of co-infected children. In many regions with high rates of both HIV and SCD, there is limited access to

diagnostic testing, specialized care, and medications. These limitations can delay the diagnosis of either condition and hinder the development of appropriate treatment plans. Inadequate healthcare facilities and a shortage of trained healthcare professionals further complicate the ability to deliver the necessary comprehensive care. To overcome these challenges, there is a need for increased healthcare investment, greater access to diagnostic tools, and more training for healthcare providers to address the unique needs of children with both HIV and SCD.[27-28]

Pathophysiological Interactions and Implications for Management

The pathophysiological interactions between HIV and sickle cell disease (SCD) in pediatric patients are complex and multifactorial, with each condition exacerbating the other's clinical manifestations. HIV primarily targets the immune system, leading to immune suppression, which increases susceptibility to opportunistic infections and hinders the body's ability to combat other diseases. On the other hand, sickle cell disease, a genetic disorder of hemoglobin, causes abnormal red blood cell formation, leading to vaso-occlusive crises, hemolysis, and tissue damage. The interaction between these two diseases significantly affects the clinical course and complicates management. HIV-related immune suppression can exacerbate the severity of SCD complications, such as pain crises and infections, which in turn can lead to increased frequency of hospitalizations and poorer overall health outcomes for pediatric patients.[29-30] The inflammatory response in both HIV and SCD has significant implications for disease progression and management. In SCD, vaso-occlusive crises occur when sickled red blood cells block blood flow in the microvasculature, leading to ischemia, pain, and tissue damage. This inflammatory response is amplified by the immune dysregulation caused by HIV, which can further impair vascular function and increase the risk of severe, prolonged crises. Additionally, the immune dysregulation seen in HIV patients can diminish the body's ability to mount an appropriate inflammatory response during a pain crisis, delaying recognition and treatment. This exacerbates the clinical picture, making it more challenging for healthcare providers to manage both conditions simultaneously. The combined inflammatory processes of HIV and SCD also contribute to multi-organ dysfunction, including kidney, liver, and cardiovascular complications, making it critical to address both conditions in a coordinated manner to prevent long-term organ damage.[31-34]

From a therapeutic perspective, the pathophysiological interactions between HIV and SCD necessitate careful consideration of treatment regimens. Antiretroviral therapy (ART) is essential for managing HIV, but certain ART drugs can have negative interactions with the drugs used to manage SCD. For instance, protease inhibitors, commonly used in ART, can induce renal toxicity, which is a particular concern for children with SCD, who are already at an increased risk for nephropathy. Similarly, nucleoside reverse transcriptase inhibitors (NRTIs), which are often part of HIV treatment regimens, can lead to mitochondrial dysfunction, further complicating SCD-related cellular damage. The management of SCD often involves the use of hydroxyurea, a medication that reduces the frequency of vaso-occlusive crises by increasing fetal hemoglobin levels. However, the immunosuppressive effects of hydroxyurea may interact with ART, potentially leading to increased viral replication or immune suppression. Therefore, careful selection of ART and SCD therapies, based on the individual patient's clinical condition and disease progression, is crucial to minimizing adverse interactions and optimizing therapeutic outcomes.[35-37] Additionally, the presence of both HIV and SCD in pediatric patients heightens the risk of multi-organ damage, particularly in the kidneys, heart, and brain. HIV-associated nephropathy (HIVAN) is a common complication of untreated HIV infection, and children with SCD are already at an increased risk for renal dysfunction due to hemolysis and vasculopathy. The combination of these two risk factors significantly increases the likelihood of kidney

disease, requiring vigilant monitoring and proactive management. Similarly, stroke is a well-known complication in children with SCD, and HIV infection may further elevate the risk due to the immunosuppressive effects of the virus and the increased likelihood of infections that can predispose to vascular damage. Therefore, understanding the pathophysiological interactions between these diseases is essential for identifying high-risk individuals and implementing appropriate preventive measures.[38-39] Psychosocial and developmental factors also play a significant role in managing the pathophysiological effects of both HIV and SCD. Chronic pain, frequent hospitalizations, and the stigma associated with HIV and SCD can severely impact a child's emotional and psychological well-being. The added burden of managing two chronic conditions requires careful attention to the mental health and social support needs of both the child and their family. Psychological distress can negatively affect treatment adherence, further complicating the management of both HIV and SCD. Interventions that address these psychosocial issues, such as counseling, family support, and peer groups, are crucial in ensuring the child's overall well-being and successful management of both diseases.[41-42]

Therapeutic Strategies and Multidisciplinary Care

The management of pediatric patients with both HIV and sickle cell disease (SCD) requires a tailored, multi-faceted therapeutic approach that addresses the complexities of each disease while considering their interactions. A critical component of treatment is the use of antiretroviral therapy (ART) to control HIV infection and prevent immune system deterioration. ART regimens must be carefully selected to avoid adverse interactions with SCD treatments, such as hydroxyurea, which is commonly used to reduce the frequency of vaso-occlusive crises. While ART improves immune function and reduces the viral load in HIV-positive patients, certain ART drugs—like protease inhibitors and NRTIs—can exacerbate complications such as renal toxicity, which is a significant concern for children with SCD. The selection of ART should therefore be individualized, with close monitoring for potential side effects and organ damage.[43-44] Hydroxyurea, a cornerstone therapy for SCD, is often used in children to reduce the frequency and severity of pain crises and acute complications like stroke. However, it is important to be cautious when combining hydroxyurea with ART due to the immunosuppressive effects of both treatments. An individualized approach to dosing, based on the patient's hematologic response to hydroxyurea and immune status, is essential. Other therapies, such as blood transfusions or bone marrow transplantation, may be considered in patients with severe SCD or inadequate response to hydroxyurea. Blood transfusions help manage anemia and reduce the risk of stroke, while stem cell transplants offer a potential curative treatment for both SCD and HIV. However, the risks of graft rejection, opportunistic infections, and immune-related complications must be carefully weighed.[45]

Multidisciplinary care plays a pivotal role in managing pediatric patients with both HIV and SCD. Effective management requires the collaboration of several healthcare professionals, including pediatric hematologists, infectious disease specialists, nephrologists, and mental health professionals. Pediatric hematologists guide the treatment of SCD, while infectious disease specialists oversee HIV management, ensuring that ART regimens are effective and safe for the patient. Nephrologists are essential in monitoring kidney function, as both SCD and HIV can lead to renal complications. Given the potential for chronic pain, which is common in both diseases, pain management specialists can offer targeted approaches to alleviate discomfort while minimizing reliance on opioids. Psychologists and social workers are integral in addressing the psychosocial and emotional challenges faced by these children, providing counseling, support for medication adherence, and assistance with coping strategies. A collaborative, coordinated effort ensures that all aspects of the child's health are managed holistically.[46]

One of the most significant challenges in the treatment of these children is the need to address the psychological and emotional toll of living with two chronic conditions. The stigma associated with both HIV and SCD can have profound effects on a child's mental health, leading to anxiety, depression, and social isolation. Addressing these issues through counseling, peer support, and family-based interventions is crucial to improving the child's quality of life and ensuring adherence to treatment regimens. Pain, which is a frequent and debilitating symptom of both conditions, is another aspect that requires careful attention. A comprehensive pain management plan should involve a combination of pharmacologic treatments, including non-opioid analgesics, corticosteroids, and adjuvant therapies such as physical therapy, along with psychosocial interventions to help children cope with chronic discomfort.[47] Immunization strategies are also important in managing pediatric patients with HIV and SCD, as these children are at increased risk for infections due to immune dysfunction and compromised spleen function. Vaccination schedules should be carefully monitored, and children should receive pneumococcal, meningococcal, and other vaccines to prevent infections that could exacerbate both conditions. Timely and proactive care in managing infections is crucial, as infections can precipitate sickle cell crises and cause significant morbidity in children with HIV. Moreover, regular screenings for complications such as stroke, retinopathy, and nephropathy are essential, as these can be exacerbated by both diseases.[48]

Conclusion

The management of pediatric patients with both HIV and sickle cell disease (SCD) presents unique challenges that require an integrated, multidisciplinary approach. These two chronic conditions interact in ways that complicate diagnosis, treatment, and long-term care, highlighting the need for careful, individualized therapeutic strategies. Antiretroviral therapy (ART) plays a crucial role in controlling HIV, but its potential interactions with treatments for SCD—such as hydroxyurea—must be carefully managed to avoid adverse effects. Similarly, the use of hydroxyurea, blood transfusions, and other SCD-specific interventions must be tailored to each child's needs, considering the complexities introduced by HIV. Multidisciplinary care is paramount to the effective management of pediatric HIV and SCD, with pediatric hematologists, infectious disease specialists, nephrologists, pain management experts, and mental health professionals all playing critical roles in providing comprehensive care. This approach not only addresses the physical and medical needs of these children but also ensures that psychosocial issues, such as pain management, emotional distress, and social stigma, are addressed. In particular, managing chronic pain, promoting adherence to treatment, and providing adequate psychological support are essential components of improving the quality of life for these children.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle

cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in

US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management.

Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.
46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12
47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24
48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com
	Subject: Haematology
DOI: 10.22192/ijcrcps.2025.12.02.003	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2025). HIV and Sickle Cell Disease: Challenges in Pediatric Management. Int. J. Curr. Res. Chem. Pharm. Sci. 12(2): 26-34.
DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.02.003

